# Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen

> **NCT00436007** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 511 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** GSK 257049
- **BIOLOGICAL:** Tritanrix™ HepB/Hib
- **BIOLOGICAL:** Rouvax™
- **BIOLOGICAL:** Stamaril™
- **BIOLOGICAL:** Polio Sabin™

## Key facts

- **NCT ID:** NCT00436007
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-30
- **Primary completion:** 2008-09-15
- **Final completion:** 2009-10-07
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436007, "Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00436007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*